BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock closed at $6.36 on 5/15/24 after a major increase of 18.7%. Moreover, this advance was accompanied by exceptionally high trading volume at 288% of normal. The stock has risen 20.9% during the last week but has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
BCRX is expected to continue to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
BioCryst Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment